Research map: Sequencing and switching among IL-17 and IL-23 biologics in plaque psoriasis: real-world lessons and precision strategies for the future

Back to the article

Papers in this map

  1. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations · Alexander Nast · 2020 · 420 citations · Cited by this paper
  2. Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience – the APEX study · 2026 · Related
  3. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management · Ditte Marie Lindhardt Saunte · 2016 · 270 citations · Cited by this paper
  4. Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease · 2026 · Related
  5. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial · Xenofon Baraliakos · 2020 · 194 citations · Cited by this paper
  6. Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study · 2026 · Related
  7. Psoriasis · April Wang Armstrong · 2025 · 187 citations · Cited by this paper
  8. Anakinra treatment practices in colchicine-resistant familial Mediterranean fever: a survey of pediatric rheumatologists conducted through the PReS AID-WP and the Turkish pediatric rheumatology associations · 2026 · Related
  9. The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis · Joachim Sieper · 2019 · 145 citations · Cited by this paper
  10. Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications · 2026 · Related
  11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis · É. Sbidian · 2023 · 131 citations · Cited by this paper
  12. Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials · 2026 · Related
  13. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources · Linda Davidson · 2021 · 127 citations · Cited by this paper
  14. The role of monoclonal antibodies in the treatment of lupus nephritis · 2026 · Related
  15. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study · Knut Schäkel · 2023 · 114 citations · Cited by this paper
  16. Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China · 2026 · Related
  17. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis · Sarah E. Thomas · 2024 · 59 citations · Cited by this paper
  18. Biosimilars as antivirals: scientific and regulatory readiness for rapid, cost-effective deployment in infectious threats · 2026 · Related
  19. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies · Jorge R. Georgakopoulos · 2018 · 56 citations · Cited by this paper
  20. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study · Irina Gasslitter · 2019 · 55 citations · Cited by this paper
  21. Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study · Matteo Megna · 2022 · 55 citations · Cited by this paper
  22. IL‐17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase · Nadine Petitpain · 2021 · 54 citations · Cited by this paper
  23. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis · Shuwei Wu · 2023 · 54 citations · Cited by this paper
  24. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) · Luigi Gargiulo · 2024 · 54 citations · Cited by this paper
  25. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience · Andrea Conti · 2018 · 45 citations · Cited by this paper
  26. Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience · Claudio Bonifati · 2020 · 44 citations · Cited by this paper
  27. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study · Christian Kromer · 2020 · 41 citations · Cited by this paper
  28. Curing Psoriasis · Su M. Lwin · 2024 · 33 citations · Cited by this paper
  29. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis · Therezia Bokor‐Billmann · 2018 · 32 citations · Cited by this paper
  30. Association of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients · Cristina Aguilar-Flores · 2020 · 28 citations · Cited by this paper
  31. IL-17A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience · Shany Sherman · 2019 · 27 citations · Cited by this paper
  32. Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual Level · Mia‐Louise Nielsen · 2022 · 25 citations · Cited by this paper
  33. Effectiveness of brodalumab after previous treatment failure of interleukin‐ 17A inhibitors in patients with psoriasis · Nikolai Loft · 2021 · 22 citations · Cited by this paper
  34. Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis · Andrew Blauvelt · 2022 · 22 citations · Cited by this paper
  35. IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis · Pushkar Aggarwal · 2024 · 20 citations · Cited by this paper
  36. Machine learning model for predicting outcomes of biologic therapy in psoriasis · Amy Du · 2023 · 17 citations · Cited by this paper
  37. Efficacy of in‐class interleukin‐23 inhibitor switching: risankizumab following guselkumab failure in moderate‐to‐severe psoriasis treatment · R. Reddy · 2020 · 16 citations · Cited by this paper
  38. Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study · Matteo Megna · 2024 · 16 citations · Cited by this paper
  39. Efficacy of switches within the class of IL ‐17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy ( BIOREP ) · Martin Tichý · 2022 · 15 citations · Cited by this paper

Source: OpenAlex (CC0)